Top 10 Pharma Companies in World 2016

Posted in Top Brand Lists, Total Reads: 6538

Pharmaceutical sector is one of the most important sectors as it not only generates revenue and contributes to economy but also works on the betterment of the race, eradication of diseases and overall welfare. The top pharmaceuticals companies in the world include likes of Johnson & Johnson, Novartis, Roche along with brands like Pfizer, Merck, Sanofi, GSK. AstraZeneca and Bayer complete the list. Here is the list of Top 10 Pharmaceutical Companies in the World 2016.

Quick Glance:

The Top Pharma Companies in the World are :

1st Place : Johnson & Johnson

2nd Place : Roche

3rd Place : Novartis

4th Place : Pfizer

5th Place : Merck

6th Place : Sanofi

7th Place : GlaxoSmithKline

8th Place : Gilead

9th Place : Bayer

10th Place : AstraZeneca

For More details about parameters and rankings, read on.

10. AstraZeneca

AstraZeneca is a British-Swedish global biopharmaceutical company founded in 1999 and headquartered in London, UK.

AstraZeneca has an employee count of over 50000 and MedImmune is a subsidiary of AstraZeneca. AstraZeneca was featured #455 in the Global Fortune 500 Companies list.

Annual revenue of $24.708 billion, R & D expenditure of $5.997 billion and a basic EPS of $2.23 made AstraZeneca helped AstraZeneca feature in the top 10 global pharmaceutical companies list.

The core business areas of AstraZeneca are classified into (a) Respiratory, Inflammation and Autoimmunity, contributing to 20.2% of annual revenue, 2015 (b) Oncology and Metabolic diseases, contributing to 38.4% of annual revenue, 2015 (c) Oncology, contributing to 11.4% of annual revenue, 2015 and (d) Infection, Neuroscience, and Gastrointestinal, contributing to 25.7% of annual revenue, 2015. New Oncology drugs like Lyparza, Iressa and Tagrisso were introduced in 2015, as well, adding to the revenue.

AstraZeneca continuously works on bringing innovative healthcare solutions to the market and an instance that showcases it is the passing of the biological drug named Benralizumab for people suffering from severe asthma in the final stages of clinical trials. This drug will actually bring a difference to the patients as it treats the root cause of the illness and not the symptoms.

Annual Revenue: 24.708 billion USD

R & D Expenditure: 5.997 billion USD

Basic EPS: 2.23 USD

Looking for Similar Lists, Browse more Top Lists

Share this Page on:
Facebook ShareTweetShare on Linkedin